| name | icsm-restrict-tt-investigational-bcr-metastatic |
| description | States that testosterone therapy should be restricted to investigational protocols in patients with biochemical recurrence or metastatic prostate cancer due to unknown long-term risks. Triggers when a clinician encounters a patient with rising PSA after definitive treatment or metastatic disease and low testosterone, questioning whether testosterone can be used outside a trial. |
Restrict testosterone therapy to investigational use in biochemical recurrence or metastatic disease
STEP 1 — Gather Information
Confirm prostate cancer treatment history, document PSA trend (rising after surgery/radiation or metastatic imaging), measure total testosterone, assess hypogonadism symptoms, review contraindications, and identify any available investigational testosterone trials.
STEP 2 — Rule In / Rule Out
Is there documented biochemical recurrence (confirmed rising PSA after definitive local therapy) or metastatic prostate cancer? If yes, proceed; if no, follow standard testosterone therapy guidelines for hypogonadism.
STEP 3 — Classify or Stratify
Determine if the patient is eligible for an investigational testosterone protocol (e.g., enrolled in an IRB‑approved trial, expanded access, or registry study) versus ineligible due to lack of available study or exclusion criteria.
STEP 4 — Decide
If eligible for investigational therapy, offer enrollment and obtain informed consent; if not eligible, do not prescribe testosterone outside a trial and manage hypogonadism symptoms with lifestyle measures, PDE5 inhibitors, or other non‑testosterone approaches.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe testosterone empirically for symptomatic hypogonadism in BCR or metastatic PCa outside a formal research protocol; avoid assuming safety based on data from non‑cancer populations; monitor PSA closely if off‑label use occurs; recognize that long‑term oncologic risks remain unknown.
Concrete Clinical Example
A 68‑year‑old man status post radical prostatectomy presents with PSA rising from 0.2 to 1.5 ng/mL over 6 months, total testosterone 8 nmol/L, fatigue, and low libido. He inquires about testosterone replacement. Because he has biochemical recurrence, testosterone should only be given under an investigational protocol; he is referred to a clinical trial of testosterone in BCR. If no trial is available, symptomatic management with exercise optimization and a PDE5 inhibitor is advised.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036
